Techniques commonly employed in the field of cognitive neuroscience (described here as neuroscience techniques) are increasingly being used to investigate the likely impact of tobacco control measures. The overarching premise of our narrative review is that these techniques can complement and extend self-report and behavioral research approaches commonly used to evaluate tobacco control measures. First, we describe how neuroscience techniques can overcome some of the limitations of these other research techniques. Second, we provide a review of studies using eye tracking, electroencephalography (EEG), and functional magnetic resonance imaging (fMRI; see Box 1 for a more detailed description of these techniques) to evaluate these policies, with a particular focus on standardized cigarette packaging and health warnings.
packaging and health warnings. Third, we discuss the limitations of these techniques. We conclude with a discussion of the future of neuroscience techniques for tobacco control research and provide a framework for future research.

Overcoming the Limitations of Other Methodologies

Every research methodology has its limitations (and we discuss limitations with neuroscience techniques later). However, techniques used in neuroscience can overcome some of the limitations associated with methodologies often used to examine questions related to tobacco control policies, including those relying on subjective responses.

Providing More Objective Measures

Traditionally, research examining the potential effectiveness of tobacco control measures has relied on subjective response methodologies, such as surveys, focus groups, and questionnaires. A recent systematic review of 68 experimental studies comparing text-only warnings with pictorial health warnings identified a total of 278 outcome measures characterizing 61 constructs across these studies.1 Of these, only 23 outcomes were objective (visual attention $n = 10$, recall/recognition $n = 5$, response time $n = 3$, quitline calls $n = 1$, and smoking behavior $n = 4$). Despite considerable converging evidence,2–4 tobacco industry advocates argue that approaches relying on subjective reports do not constitute “credible evidence.”4 Tobacco industry criticisms on the grounds of a lack of credible evidence are likely to have slowed United Kingdom government decision-making on standardized packaging5,6 and US decision-making on health warnings.7 Indeed, as intentions are known to only play a small role in actual behavior, research which relies on self-reported outcomes has also been criticized by academics within the field of tobacco control who have argued that experimental designs with reliable, behavioral measures are required to provide “convincing evidence.”9 Neuroscience techniques allow us to examine processes and behaviors that are outside of the awareness of individuals and therefore are not subject to these same criticisms.

Facilitating Investigation Where Behavioral Manipulations Are Not Possible

Behavioral research methodologies can indeed provide more convincing evidence of the effects of a proposed tobacco control measure. A recent randomized controlled trial evaluated the effects of pictorial cigarette pack warnings on quit attempts,10 while another has examined the impact of standardized packaging on actual smoking behavior.11 Similarly, in a recently completed randomized controlled trial, the effects of reducing the nicotine content in cigarettes on smoking behavior over 6 weeks were evaluated in a diverse sample of US smokers.12 The results provide more compelling evidence than would a survey study asking smokers to self-report on their opinions or imagined reactions to a reduced-nicotine cigarette. However, while studies with behavioral outcomes provide a more rigorous evaluation of potential policy measures than those relying on subjective reports, these evaluations can take years to complete and require large sample sizes and long follow-up periods in order to observe the downstream effects of these interventions.13

In addition, behavioral outcomes are not possible when the policy manipulation is outside the control of the experimenter. For example, it is typically not feasible to randomly assign half of a country to a tobacco control measure such as standardized packaging and compare its effects on smoking outcomes to the half of the population continuing with normal practice. Instead, policymakers will wait for evidence from other countries that have introduced a tobacco control measure before implementing it themselves. For example, the United Kingdom, Ireland, and France waited for pre/postevaluations of the effectiveness of standardized packaging in Australia14–16 before implementing it. However, this is not always feasible, and generalizing from one country to another is an important limitation of this kind of evaluation. Neuroscience techniques can provide objective evidence of the likely effects of a tobacco control measure but in a considerably shorter timescale.

Allowing a Deeper Analysis of Cognitive Mechanism

Studies with behavioral outcomes, while providing evidence regarding the impact of policy on target endpoints, are also limited in their ability to explain why a policy intervention worked in the manner it did. Neuroscience techniques have been important in informing our understanding of the cognitive mechanisms underlying tobacco smoking, including nicotine withdrawal17,18 the impact of quitting smoking,19 prediction of cessation outcomes,20–23 and cue reactivity.24–26 These techniques are increasingly being used to examine the cognitive mechanisms underlying responses to tobacco control measures. In some cases, insights into cognitive mechanism may be obvious (eg, nicotine is the primary psychoactive component of tobacco smoke, and reducing it to negligible levels decreases smoking reinforcement) or unimportant. However, in other cases, a deeper understanding of how a policy manipulation exerts its influence can result in insights necessary for further refinement and even greater impact. For example, understanding why a particular health warning is effective at encouraging thoughts about quitting can inform development of future health warnings. Furthermore, while a group of participants in a study may all exhibit the same self-reported or behavioral response to one stimulus or manipulation, the underlying cognitive and neural processes by which they arrive at those outcomes may vary in meaningful ways.

The Use of Neuroscience Techniques in Tobacco Control Research

By measuring processes and behaviors that are outside of the awareness of individuals, neuroscience techniques can overcome many of the limitations of methodologies relying on both subjective and behavioral responses. These techniques include eye tracking, EEG, and fMRI and are commonly used in market research to understand how neuroscience can inform consumer decision-making and increase purchasing behavior.27–29 Box 1 describes these techniques in more detail, and in the following sections, we provide a review of studies using these techniques to answer tobacco policy-relevant questions, with the goal of ultimately reducing purchasing of tobacco by reducing smoking initiation and encouraging cessation.
Box 1. Neuroscience Techniques Explained

Eye tracking

Attention to a stimulus is recognized as an important prerequisite for behavior change.44 While early eye trackers were invasive and relied on direct and invasive observations of the eye, today’s eye trackers typically measure eye movements using noninvasive optical tracking with a video-based eye tracker. At the most basic level, eye movements can be divided into fixations (when the eye is stable in a particular location) and saccades (when it is moving to another location). Researchers typically examine the location of the first fixation, the duration of fixations, or the number of fixations. These measures provide an indication of visual attention toward a stimulus (ie, a tobacco health warning). Eye trackers are either “static” or “mobile.” When using a static eye tracker, the participant is static and views 2D stimuli on screen (either still or moving images). By contrast, using a mobile eye tracker allows for analysis of eye movements when individuals are mobile in naturalistic or real-world environments.

Eye tracking can be used to answer questions such as “Which elements of pro/anti-tobacco messages capture attention?” “How is attention allocated in tobacco retail environments?” “How does attention to vaping cues influence later smoking behavior?”

Electroencephalography

During EEG, electrodes are placed over the skull to measure changes in the electric field being produced by the brain. Event-related potentials (ERPs), which reflect the specific electrical activity related to a specific sensory “event” (ie, seeing an image on a computer screen), can be measured using EEG. ERPs can refer to different components, such as P300, where each component is typically quantified by its amplitude and latency related to the onset of the sensory event. Although EEG has poor spatial resolution (ie, it is difficult to determine exactly where in the brain the electrical activity is coming from), EEG affords excellent temporal resolution (within the millisecond range), meaning that it is useful for measuring brain activity over time. A large volume of literature has previously used EEG to explore the mechanisms underlying tobacco addiction and the P300 ERP, which is related to attentional processes, and participant arousal state has been reliably shown to reflect the heightened incentive value of smoking cues among smokers.42

EEG can be used to answer questions such as “Do anti-tobacco advertisements successfully elicit emotional responses?” “What are the neural indices underlying smokers’ reactance to health warnings?” “What is the minimum nicotine content needed to induce change in neural activity?”

Functional magnetic resonance imaging

The basic principle behind functional magnetic resonance imaging (fMRI) is that when a region of the brain is more active, it uses more oxygen, resulting in an increased blood flow to this region. fMRI works by detecting these changes in blood oxygenation and flow and measures blood oxygenation–level dependent (BOLD) signal in the brain. Unlike EEG, fMRI has relatively poor temporal resolution (~1 s) because of the slower speed of blood when compared with electrical impulses. However, the spatial resolution of fMRI (approximately 1–2 mm) is much greater than EEG, meaning that fMRI can be used to create maps that show the activated regions of the brain during certain tasks. fMRI is therefore important in understanding the neural mechanisms underlying behavior change.

fMRI can be used to answer questions such as “How do tobacco advertisements influence neural responses to reward?” “What effect does vaping during scanning have on neural responses related to reward and craving?” “How do neural responses to anti-tobacco messages predict later choice of tobacco products above and beyond self-report?”

Eye Tracking

Eye tracking has been used for decades by consumer marketers, from studies examining visual attention to adverts in the Yellow Pages to those exploring the cognitive mechanisms underlying supermarket choices.45 This methodology provides an objective measure of what visual stimuli or objects individuals are attending to, and which aspects of the environment capture attention. The value of this research technique is also recognized by the tobacco industry, who have used mobile eye tracking (see Box 1) to examine the impact of tobacco point-of-sale displays on visual attention.46 Similar research has been conducted by academics.33

One of the mechanisms through which standardized packaging is expected to be effective is by increasing the salience of health warnings.2,3 Research using eye-tracking technology has therefore been particularly valuable in objectively measuring visual attention to health warnings on branded and standardized packaging, observing that standardized packaging increases visual attention to warnings among adult and adolescent nonsmokers and nondaily smokers.24-47 Other research has found that this is observed for text-only warnings and pictorial health warnings on standardized packs.48 Eye-tracking research was cited in the legal case between British American Tobacco and the UK Department of Health regarding the legality of standardized packaging legislation and was described as using “objective physiological techniques.” This research adds weight to and extends findings obtained using other research methodologies, including focus groups,40,41 quantitative surveys,42,43 and naturalistic studies,44,45 which have reported similar effects.

By measuring which components of a health warning smokers are attending to and consequently which are impacting their self-reported reactions, eye-tracking technology allows greater understanding of the cognitive mechanisms underlying the influence of tobacco marketing materials on self-reported reactions and behavioral effects (see Figure 1a and b and Box 1 that demonstrate how eye tracking can be used to examine attention to discrete regions of a cigarette pack advertisement). This is particularly important, as eye-tracking research suggests that daily smokers avoid currently used warnings, indicating that different strategies for capturing attention are required among this population. Studies using this technique have examined the impact of varying a number of different health warning components including novelty,46,47 size,48 format,49,50 and emotional content51 on visual attention. Other research has used eye tracking to examine the impact of risk statements,52 message congruency,53 and pictorial warnings54 in cigarette advertisements on visual attention.
Electroencephalography

Despite considerable research showing that pictorial warnings are more effective than text-only warnings, the literature on which types of pictorial warnings are more effective and the psychological processes underlying responses to them is less well understood. For example, a number of self-report studies have found that pictorial warnings evoke both positive (ie, increased warning credibility and cognitive elaboration) and negative responses (ie, negative affective reactions and psychological reactance). By examining correlations between self-reported reactions and brain activation, EEG and specifically examination of particular event-related potentials (see Box 1) have allowed us to begin to understand the cognitive mechanisms underlying these self-reported responses.

Stothart et al. used EEG to understand the cognitive mechanism underlying avoidance of health warnings among smokers, a finding previously observed using both self-report and eye-tracking research. While smokers showed no differences in early perceptual processing when compared with nonsmokers (as indexed by the P1, P300, and visual mismatch negativity event-related potentials), they showed reduced later cognitive responses to the warnings.

Figure 1. (a) Typical desk-mounted eye tracker setup (image from Flickr—https://flic.kr/p/7YWwiE); (b) eye-tracking data from a single participant showing the focus of visual attention when viewing two different cigarette packs (cigarette packs photographed by OMM and branding information blanked out). Unpublished data taken with permission from OMM; (c) typical EEG setup (image with permission from the School of Experimental Psychology, University of Bristol); (d) difference waveforms (ie, responses to health warnings subtracted from responses to control stimuli) illustrating greater emotional response (as measured using the late positive potential) to warnings for nonsmokers versus daily smokers. Data taken with permission from Stothart et al.; (e) typical fMRI setup (image with permission from the School of Experimental Psychology, University of Bristol); and (f) brain activation associated with processing of high emotional reaction (ER) compared with low ER warnings. Data taken with permission from Wang et al.
as well as allow for the comparison of valuation across product categories (eg, cigarette packs vs. conventional cigarettes). The potential of this mixed methodological approach in the field of tobacco control has been demonstrated by Falk et al. who found that the extent to which antismoking messages activated the medial prefrontal cortex predicted the success of those same antismoking messages at the population level. Combining neural data with self-reported responses to the campaign accounted for the largest proportion of the variation in the population-level success of the campaign, demonstrating the added value of the neural predictor. Similarly, activation in the medial prefrontal cortex has been shown to be predictive of successful smoking cessation (as measured using expired carbon monoxide) over and above self-reported intentions to quit, self-efficacy, and the ability to relate to health messages. This technique could therefore be used to augment self-report measures which are typically used as predictors of behavior and may be particularly useful when self-reported preferences and actual behavior are likely to diverge (ie, due to social desirability bias).

**Limitations of Neuroscience Techniques and Possibilities for the Future**

Although these neuroscience research techniques can be valuable adjuncts to other experimental and qualitative research and can provide important insights into the potential cognitive mechanisms underlying the effectiveness of tobacco control measures, they also have some important limitations.

**Ecological Validity**

While these techniques afford excellent internal validity, allowing researchers to manipulate different elements of the tobacco control measure (ie, the type of health warning or the color of the “standardized” packaging), their ecological validity is limited. However, these limitations are not insurmountable. Indeed, there is a long history of using these techniques in market research to answer questions related to consumer behavior.

Purchasing behavior can be modeled during fMRI by giving subjects a set amount of money that can be allocated across purchasing decisions with later, real-world delivery of those products. Recently, researchers have conducted the first feasibility trial demonstrating the use of an e-cigarette during fMRI scanning. Furthermore, with improvements in technology, neuroscience techniques are increasingly being taken into real-world environments. For example, mobile EEG and eye tracking equipment allow us the possibility of examining neural responses and visual attention in the real world, such that the impact of real, 3D cigarette packs on visual attention to health warnings can be assessed. In addition, a growing number of studies are bringing real-world, personally relevant stimuli into the lab and scanning environment for assessment of subjective and neural reactivity; in the future, such methods could be applied to the study of real-world tobacco retail and point-of-sale environments. Furthermore, recent advances in virtual reality (VR) technology mean that some of the limitations of these neuroscience techniques can be overcome even in controlled laboratory settings. Using VR headsets, participants can be immersed in life-like scenes in combination with neuroscience techniques. This technology has been used to investigate the impact of smoking cues in VR environments on craving, and as a result, the impact of VR smoking cue exposure therapy on smoking cessation success. Moreover, at least three studies have evaluated craving and tobacco product purchasing behaviors in virtual tobacco retail outlets. As far as we are
aware, however, VR has yet to be combined with simultaneous eye tracking, EEG, or fMRI, or other neuroscience techniques, to answer questions relevant to tobacco control.

Generalizability
In addition to relatively poor ecological validity, the degree to which findings from neuroscience research are generalizable is also a potential limitation. Indeed, it is important to determine to what extent the behaviors observed using neuroscience techniques are predictive of actual behavioral responses to tobacco control measures. For example, the extent to which visual attention to health warnings or neural responses to standardized packaging replicate that observed when a smoker pulls a cigarette pack from their pocket is unknown. Studies that use a combination of methodological approaches can attempt to bridge this gap. Neuroscience measures should be used in combination with questionnaires or biological measures (such as cotinine) to understand the relationship between the neuroscience measure and actual behavior. As described in the fMRI subsection, neural measures are increasingly being used to improve predictions of decision-making models, where neural activation predecision can predict later choices.

Other Considerations
Finally, each of the neuroscience techniques described here has several inherent limitations that researchers interested in their use should consider. These include high set-up costs and large amounts of time and skill required to run experiments and analyze the data. This technical obstacle can be overcome by forming collaborations between researchers with different research backgrounds. For a more detailed description of the techniques that have been described here, including their advantages and disadvantages, readers should refer to the review by Kable, which also outlines other techniques that have not been mentioned here, including magnetoencephalography, positron emission tomography, near-infrared spectroscopy, transcranial magnetic stimulation, and transcranial direct current stimulation.

Conclusions
This review has focused on the role of neuroscience techniques in addressing research questions related to tobacco control policies, in particular, standardized packaging and health warnings. Other possibilities for future research are also discussed in Box 1. Indeed, the scope of these research techniques goes far beyond what we have described here, and our review should therefore be seen as a springboard for future research. For instance, these techniques can be used to examine other tobacco product marketing practices including point-of-sale displays, tobacco advertisements, and mass media campaigns. Similarly, neuroscience techniques can be applied to evaluate novel strategies for restricting, modifying, or banning tobacco advertisements or to study the effects of modified tobacco products and determine their likely impact. Beyond tobacco control, these techniques can answer policy-relevant research questions in other fields, such as the potential impacts of alcohol advertisements and food labeling.

Rather than replacing more traditional methods of examining tobacco control measures, such as observational experiments, surveys, and questionnaires, neuroscience techniques should be a useful adjunct to these methods. These techniques can provide more objective evidence of the impacts of policy measures, allow investigation where it is not possible to conduct behavioral manipulations, and facilitate a deeper understanding of the cognitive mechanisms underlying the impacts of tobacco control policies. In addition, it seems that results from neuroscience studies can be more persuasive legally than those relying on more subjective methodologies. Although our research questions should not be solely led by their potential to have “impact,” this is an important consideration when working in a field with such clear implications for policy. We hope our review demonstrates that we can use the techniques developed in the consumer neuroscience literature that focus on the goal of increasing purchasing behavior and turn these on their heads to reduce tobacco purchasing.

Funding
This work was supported in part by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council and the University of Bristol (MC_UU_12013/6 and MC_UU_12013/7) and the Economic and Social Research Council (ES/R003424/1). JO was supported by the National Institute on Drug Abuse (K23 DA042898). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Declaration of Interests
None declared.

Acknowledgments
The authors thank George Stothart and An-Li Wang for providing Figure 1d and f, respectively. OMM and MRM are members of the UK Centre for Tobacco and Alcohol Studies, a UKCRC Public Health Research: Centre of Excellence, which receives funding from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, and the National Institute for Health Research, under the auspices of the UK Clinical Research Collaboration. OMM and MRM conceived the review. The first draft was written by OMM, and all authors contributed to further versions of the manuscript. All authors read and approved the final version of the manuscript.

References
1. Francis DB, Hall MG, Noar SM, Ribisl KM, Brewer NT. Systematic review of measures used in pictorial cigarette pack warning experiments. Nicotine Tob Res. 2017;19(10):1127–1137.
2. Moodie C, Angus K, Stead M, Bauld L. Plain Tobacco Packaging Research: An Update. Stirling, Scotland: Centre for Tobacco Control Research, Institute for Social Marketing, University of Stirling; 2013.
3. Moodie C, Stead M, Bauld L, et al. Plain Tobacco Packaging: A Systematic Review. Stirling, UK: University of Stirling; 2012.
4. Urquhart C. Lansley comes under fire over plain cigarette packet plans. The Guardian. 2012. 2012. https://www.theguardian.com/society/2012/apr/13/lansley-plain-cigarette-pack-plain. Accessed April 14, 2012.
5. Hatchard JL, Fooks GJ, Evans-Reeves KA, Ulucanlar S, Gilmore AB. A critical evaluation of the volume, relevance and quality of evidence submitted by the tobacco industry to oppose standardised packaging of tobacco products. BMJ Open. 2014;4(2):e003757.
6. Ulucanlar S, Fooks GJ, Hatchard JL, Gilmore AB. Representation and mis-representation of scientific evidence in contemporary tobacco regulation: a review of tobacco industry submissions to the UK Government consultation on standardised packaging. PLoS Med. 2014;11(3):e1001629.
7. FDA. Required warnings for cigarette packages and advertisements. Final rule. Fed Regist. 2011;76(20):36628–36777.
8. Webb TL, Sheeran P. Does changing behavioral intentions engender behavior change? A meta-analysis of the experimental evidence. Psychol Bull. 2006;132(2):249–268.

9. Ruitter R, Kok G. Response to Hammond et al. showing leads to doing, but doing what? The need for experimental pilot testing. Eur J Public Health. 2006;16:225.

10. Brewer NT, Hall MG, Noar SM, et al. Effect of pictorial cigarette pack warnings on changes in smoking behavior: a randomized clinical trial. JAMA Intern Med. 2016;176(7):905–912.

11. Maynard OM, Leonards U, Attwood AS, Bauld L, Hogarth L, Munafó MR. Effects of first exposure to plain cigarette packaging on smoking behaviour and attitudes: a randomised controlled study. BMC Public Health. 2015;15:240.

12. Donny EC, Denlinger RL, Tidey JW, et al. Randomized trial of reduced-nicotine standards for cigarettes. N Engl J Med. 2015;373(14):1340–1349.

13. Brewer NT, Hall MG, Lee JG, Peebles K, Noar SM, Ribisl KM. Testing warning messages on smokers’ cigarette packages: a standardised protocol. Tob Control. 2016;25(2):153–159.

14. Durkin S, Brennan E, Coomber K, Zacher M, Scollo M, Wakefield M. Short-term changes in quitting-related cognitions and behaviours after the implementation of plain packaging with larger health warnings: findings from a national cohort study with Australian adult smokers. Tob Control. 2015;24(supp 2):i26–i32.

15. Wakefield MA, Hayes L, Durkin SJ, Borland R. Introduction effects of the Australian plain packaging policy on adult smokers: a cross-sectional study. BMJ Open. 2013;3(7):e003175.

16. Zacher M, Bayly M, Brennan E, et al. Personal tobacco pack display before and after the introduction of plain packaging with larger pictorial health warnings in Australia: an observational study of outdoor café strips. Addiction. 2014;109(4):633–662.

17. Kozink RV, Kollins SH, McClernon FJ. Smoking withdrawal modulates right inferior frontal cortex but not presupplementary motor area activation during inhibitory control. Neuropsychopharmacology. 2010;35(13):2600–2606.

18. Kozink RV, Lutz AM, Rose JE, Froeliger B, McClernon FJ. Smoking withdrawal shifts the spatiotemporal dynamics of neurocognition. Addict Biol. 2012;17(4):480–490.

19. Gilbert DG, McClernon FJ, Rabinovich NE, et al. Effects of quitting smoking on EEG activation and attention last for more than 31 days and are more severe with stress, dependence, Dr2d A1 allele, and depressive traits. Nicotine Tob Res. 2004;6(2):249–267.

20. Sweitzer MM, Geier CF, Addicott MA, et al. Smoking abstinence-induced changes in resting state functional connectivity with ventral striatum predict lapse during a quit attempt. Neuropsychopharmacology. 2016;41(10):2521–2529.

21. Sweitzer MM, Geier CF, Denlinger R, et al. Blunted striatal response to monetary reward anticipation during smoking abstinence predicts lapse during a contingency-managed quit attempt. Psychopharmacology (Berl). 2016;233(5):751–760.

22. James A, Gilman J, Radoman M, Pachas G, Fava M, Evans A. Revisiting the role of the insula and smoking cue-reactivity in relapse: a replication and extension of neuroimaging findings. Drug Alcohol Depend. 2017;179(8–12).

23. Froeliger B, McConnell PA, Bell S, et al. Association between baseline corticothalamic-mediated inhibitory control and smoking relapse vulnerability. JAMA Psychiatry. 2017;74(4):379–386.

24. McClernon FJ, Kozink RV, Lutz AM, Rose JE. 24-h smoking abstinence potentiates fMRI-BOLD activation to smoking cues in cerebral cortex and dorsal striatum. Psychopharmacology (Berl). 2009;204(1):25–35.

25. McClernon FJ, Conklin CA, Kozink RV, et al. Hippocampal and insular response to smoking-related environments: neuroimaging evidence for drug-context effects in nicotine dependence. Neuropsychopharmacology. 2016;41(3):877–885.

26. McClernon FJ, Kozink RV, Rose JE. Individual differences in nicotine dependence, withdrawal symptoms, and sex predict transient fMRI-BOLD responses to smoking cues. Neuropsychopharmacology. 2008;33(9):2148–2157.

27. Smidts A, Hsu M, Sanfey AG, et al. Advancing consumer neuroscience. Marketing Lett. 2014;25(3):257–267.

28. Venkatraman V, Clifton JA, Fitzsimons GJ, Huettel S. New scanner data for brand marketers: how neuroscience can help better understand differences in brand preferences. J Consum Psychol. 2012;22:143–153.

29. Plassmann H, Venkatraman V, Huettel S, Yoon C. Consumer neuroscience: applications, challenges, and possible solutions. J Marketing Res. 2015;52(4):427–435.

30. Lobse GL. Consumer eye movement patterns on yellow pages advertising. J Advertising. 1997;26(1):61–73.

31. Russo JE, Leclerc F. An eye-fixation analysis of choice processes for consumer nondurables. J Consum Res. 1994;21(2):274–90.

32. Pollay RW. More than meets the eye: on the importance of retail cigarette merchandising. Tob Control. 2007;16(4):270–274.

33. Bansal-Travers M, Adkison SE, O’Connor RJ, Thrasher JF. Attention and recall of point-of-sale tobacco marketing: a mobile eye-tracking pilot study. AIDS Public Health. 2016;3(1):13–24.

34. Maynard OM, Munafó MR, Leonards U. Visual attention to health warnings on plain tobacco packaging in adolescent smokers and non-smokers. Addiction. 2013;108(2):413–419.

35. Munafó MR, Roberts N, Bauld L, Leonards U. Plain packaging increases visual attention to health warnings on cigarette packs in non-smokers and weekly smokers but not daily smokers. Addiction. 2011;106(8):1505–1510.

36. Maynard OM, Attwood A, O’Brien L, et al. Avoidance of cigarette pack health warnings among regular cigarette smokers. Drug Alcohol Depend. 2014;136:170–174.

37. Ramunno S, Mandeville KL, Yarrow K. The effect of plain cigarette packaging on attention to health warnings. The Lancet. 2012;380:S5.

38. Shankleman M, Sykes C, Mandeville KL, Di Costa S, Yarrow K. Standardised (plain) cigarette packaging increases attention to both text-based and graphical health warnings: experimental evidence. Public Health. 2015;129(1):37–42.

39. British American Tobacco vs Department of Health. EWHC 1169. 2016.

40. Scheffels J, Sarbo G. Perceptions of plain and branded cigarette packaging among Norwegian youth and adults: a focus group study. Nicotine Tob Res. 2013;15(2):450–456.

41. McCool J, Webb L, Cameron LD, Hock J. Graphic warning labels on plain cigarette packs: will they make a difference to adolescents? Soc Sci Med. 2012;74(8):1269–1273.

42. Wakefield M, Germain D, Durkun S, Hammond D, Goldberg M, Borland R. Do larger pictorial health warnings diminish the need for plain packaging of cigarettes? Addiction. 2012;107(6):1159–1167.

43. Al-Hamdani M. The effect of cigarette plain packaging on individuals’ health warning recall. Health Policy. 2013;103(3):68–77.

44. Moodie C, Mackintosh AM. Young adult women smokers’ response to using plain cigarette packaging: a naturalistic approach. BMJ Open. 2013;3(3):e002402.

45. Moodie C, Mackintosh AM, Hastings G, Ford A. Young adult smokers’ perceptions of plain packaging: a pilot naturalistic study. Tob Control. 2011;20(5):367–373.

46. Crespo A, Cabestreoro R, Grzib G, Quiros P. Visual attention to health warnings in tobacco advertisements: an eye-tracking research between smokers and non-smokers. Stud Psychol Med Soc Sci. 2007;49(1):39.

47. Krugman DM, Fox RJ, Fletcher JE, Fischer PM, Rojas TH. Do adolescents attend to warnings in cigarette advertising? An eye-tracking approach. J Advertising Res. 1994;34(6):39–52.

48. Klein EG, Shoben AB, Krygowski S, et al. Does size impact attention and recall of graphic health warnings? Tob Regul Sci. 2015;12(2):175–185.

49. Strasser AA, Tang KZ, Romer D, Jepson C, Cappella JN. Graphic warning labels in cigarette advertisements: recall and viewing patterns. Am J Prev Med. 2012;43(1):41–47.

50. Peterson EB, Thomson S, Lindsay G, John K. Adolescents’ attention to traditional and graphic tobacco warning labels: an eye-tracking approach. J Drug Educ. 2010;40(3):227–244.

51. Kessels LT, Ruiter RA. Eye movement responses to health messages on cigarette packages. BMC Public Health. 2012;12(1):1–9.
52. Lochbuehler K, Tang KZ, Souprontouchuk V, et al. Using eye-tracking to examine how embedding risk corrective statements improves cigarette risk beliefs: implications for tobacco regulatory policy. *Drug Alcohol Depend*. 2016;164:97–105.

53. Lochbuehler K, Mercincavage M, Tang KZ, Tomlin CD, Cappella JN, Strasser AA. Effect of message congruency on attention and recall in pictorial health warning labels. *Tob Control*. 2017;1–6. doi:10.1136/tobaccocontrol-2016-036115.

54. Noar SM, Hall MG, Francis DB, Ribisl KM, Pepper JK, Brewer NT. Pictorial cigarette pack warnings: a meta-analysis of experimental studies. *Tob Control*. 2015;25:341–354.

55. Stothart G, Maynard O, Lavis R, Munafò M. Neural correlates of cigarette health warning avoidance among smokers. *Drug Alcohol Depend*. 2016;161:153–162.

56. Hammond D, Fong GT, McDonald PW, Brown KS, Cameron R. Graphic Canadian cigarette warning labels and adverse outcomes: evidence from Canadian smokers. *Am J Public Health*. 2004;94(8):1442–1445.

57. Wang A-L, Romer D, Elman I, Turetsky BI, Gur RC, Langleben DD. Emotional graphic cigarette warning labels reduce the electrophysiological brain response to smoking cues. *Addict Biol*. 2014;20(2):368–376.

58. Cochran JR, Kydd RR, Lee JM, Walker N, Conedine NS. Disgust but not health anxiety graphic warning labels reduce motivated attention in smokers: a study of P300 and late positive potential responses. *Nicotine Tob Res*. 2017. doi:10.1093/ntr/ntx158.

59. Green AE, Mays D, Falk EB, et al. Young adult smokers’ neural response to graphic cigarette warning labels. *Addict Behav Rep*. 2016;3:28–32.

60. Maynard OM, Brooks JC, Munafó MR, Leonards U. Neural mechanisms underlying visual attention to health warnings on branded and plain cigarette packs. *Addiction*. 2017;112(4):662–672.

61. Newman-Norlund RD, Thrasher JF, Fridriksson J, et al. Neural biomarkers for assessing different types of imagery in pictorial health warning labels for cigarette packaging: a cross-sectional study. *BMJ Open*. 2014;4(12):e006411.

62. Wang A-L, Lowen SB, Romer D, Giorno M, Langleben DD. Emotional reaction facilitates the brain and behavioural impact of graphic cigarette warning labels in smokers. *Tob Control*. 2015;24(3):225–232.

63. Levy DJ, Glimcher PW. The root of all value: a neural common currency for choice. *Curr Opin Neurobiol*. 2012;22(6):1027–1038.

64. Knutson B, Rick S, Wimmer GE, Prelec D, Loewenstein G. Neural prediction of purchases. *Neuron*. 2007;53(1):147–156.

65. Falk EB, O’Donnell MB, Tompson S, et al. Functional brain imaging predicts public health campaign success. *Soc Cogn Affect Neurosci*. 2016;11(2):204–214.

66. Falk EB, Barkman ET, Whalen D, Lieberman MD. Neural activity during health messaging predicts reductions in smoking above and beyond self-report. *Health Psychol*. 2011;30(2):177–185.

67. Wall MB, Mentink A, Lyons G, Kowalczyk OS, Demetriou L, Newbould RD. Investigating the neural correlates of smoking: feasibility and results of combining electronic cigarettes with fMRI. *Sci Rep*. 2017;7:11352.

68. Duvinage M, Castermans T, Petieau M, Hoellinger T, Cherom G, Dutot T. Performance of the Emotiv Epoce headset for P300-based applications. *Biomed Eng Online*. 2013;12:56.

69. Baschung NL. Using mobile eye-tracking to assess attention to smoking cues in a naturalized environment. *Addict Behav*. 2013;38(12):2837–2840.

70. McClenon FJ, Conklin CA, Kozink RV, et al. Hippocampal and insular response to smoking-related environments: neuroimaging evidence for drug-context effects in nicotine dependence. *Neuropsychopharmacology*. 2016;41(3):877–885.

71. Conklin CA, Perkins KA, Robin N, McClenon FJ, Salkeld RP. Bringing the real world into the laboratory: personal smoking and nonsmoking environments. *Drug Alcohol Depend*. 2010;111(1–2):58–63.

72. Pericot-Valverde I, Germeroth L.J, Tiffany ST. The use of virtual reality in the production of cue-specific craving for cigarettes: a meta-analysis. *Nicotine Tob Res*. 2016;18(5):538–546.

73. Culbertson CS, Shalenberger S, De La Garza R, Newton TF, Brody AL. Virtual reality cue exposure therapy for the treatment of tobacco dependence. *J Cyber Ther Rehabil*. 2012;5(1):57–64.

74. Kim AE, Nonnemaker JM, Loomis BR, et al. Influence of point-of-sale tobacco displays and graphic health warning signs on adults: evidence from a virtual store experimental study. *Am J Public Health*. 2014;104(5):888–895.

75. Kim AE, Nonnemaker JM, Loomis BR, et al. Influence of tobacco displays and ads on youth: a virtual store experiment. *Pediatrics*. 2013;131(1):e88–e95.

76. Nonnemaker J, Kim A, Shafer P, et al. Influence of point-of-sale tobacco displays and plain black and white cigarette packaging and advertisements on adults: evidence from a virtual store experimental study. *Addict Behav*. 2016;51:15–22.

77. Kable JW. The cognitive neuroscience toolkit for the neuroeconomist: a functional overview. *J Neurosci Psychol Econ*. 2011;4(2):63–84.

78. Thomsen SR, Fulton K. Adolescents’ attention to responsibility messages in magazine alcohol advertisements: an eye-tracking approach. *J Adolesc Health*. 2007;41(1):27–34.

79. Graham DJ, Orquin JL, Visschers VH. Eye tracking and nutrition label use: a review of the literature and recommendations for label enhancement. *Food Policy*. 2012;37(4):378–382.

80. Huay E. The Psychology and Pedagogy of Reading. The Macmillan Company; 1908.

81. Polich J, Kok A. Cognitive and biological determinants of P300: an integrative review. *Biol Psychol*. 1995;41(2):103–146.

82. Littel M, Euser AS, Munafò MR, Franken IHA. Electrophysiological indices of biased cognitive processing of substance-related cues: a meta-analysis. *Neurosci Biobehav Rev*. 2012;36(8):1803–1816.